The purpose of this study was to evaluate the efficacy and safety of fexofenadine hydrochloride on the basis of standard treatment after PCI in STEMI patients.
Ages above 18;
Being able to verbally confirm understanding of the trial risks, benefits, and treatment options of receiving treatment with fexofenadine hydrochloride. He/she or his/her legal representative shall provide written informed consent before participating in the clinical trial.
Clinical symptoms: ischemic chest pain lasting for over 30 minites;
Elevated serum cTn: at least once higher than the upper limit of normal values (99th percentile of the reference upper limit);
Long term use of fexofenadine hydrochloride or other H1 receptor inhibitors;
Previously suffered from myocardial infarction or received coronary artery bypass grafting;
History of severe renal failure, estimated glomerular filtration rate (eGFR) < 30ml/min;
History of severe liver dysfunction, total bilirubin (TBil) > the upper limit of normal, or AST/ALT > 3 times the upper limit of normal, or alkaline phosphatase > 2.5 times the upper limit of normal;